
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma.
Case: A 75-Year-Old Woman With Multiple Myeloma
Initial Presentation
Clinical Workup
Treatment



